Gemstone Biotherapeutics For Profit
.jpg)
StemBioSys develops proprietary stem cell technologies for the regenerative medicine market.
%20University%20System%20of%20Maryland.png)
Last Funding Type:
Post-IPO Equity
Headquarters:
United States
Investors Number:
5
Technology:
Other
Industry:
Regenerative medicine
Estimated Revenue:
$10M to $50M
Total Funding:
$69.9M